Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: Celea Therapeutics has dosed the first patient in the Phase 3 SURPASS-IPF trial testing deupirfenidone against pirfenidone for idiopathic pulmonary fibrosis.
Pharma & Biotech

What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment

Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.

Read More
Aravind Eye Care System and Alcon’s new Coimbatore retina training centre is designed to strengthen vitreoretinal surgical skills and expand access to specialist eye care worldwide. Representative image.
Pharma & Biotech

Brent Saunders exits Bausch + Lomb just as earnings improve. What changes under Thomas Appio?

Bausch + Lomb names Thomas Appio interim CEO as both companies expect higher 2026 EBITDA guidance. October 28 results will test momentum.

Read More
Tract Bio’s TP101 and stemECHO research targets drug-resistant cancer stem cells through preclinical combination testing and functional precision medicine screening. Representative image.
Pharma & Biotech

Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone

Bristol Myers Squibb's RYZ101 meets its Phase 3 endpoint after lutetium-177 treatment, advancing alpha radiopharmaceutical development.

Read More
Artificial intelligence-powered coronary CT angiography is being studied to identify high-risk heart lesions before myocardial infarction. Representative image.
Medical Devices & Diagnostics

Can Teleflex’s Freesolve scaffold challenge permanent drug-eluting stents?

Teleflex completes BIOMAG-LL enrollment in 102 patients, testing longer Freesolve magnesium scaffolds ahead of European regulatory expansion.

Read More
Psoriasis treatment innovation moves closer to market as the US Food and Drug Administration grants Priority Review to Takeda’s zasocitinib following positive Phase 3 trial results, including head-to-head superiority over deucravacitinib in plaque psoriasis. Representative image.
Pharma & Biotech

Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis

Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.

Read More
Representative image of an oral obesity treatment concept illustrating how Eli Lilly and Company’s Foundayo approval could widen access to GLP-1 weight loss therapy and reshape the next phase of the obesity drug market.
Pharma & Biotech

Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement

Eli Lilly's Taltz and Zepbound show broader immune and metabolic biomarker changes in psoriasis, building on Phase 3b skin clearance results.

Read More
Representative image: Retinal imaging illustrates geographic atrophy as Ocugen advances OCU410 into Phase 3 testing as a potential one-time gene therapy for dry age-related macular degeneration.
Pharma & Biotech

Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy

Perceive Bio completes 94-eye VOY-101 enrollment for geographic atrophy. Examine trial design, safety, competition and the 2027 readout.

Read More
Medtronic’s Affera Mapping and Ablation System with the Sphere-9 catheter has gained an expanded European CE Mark for ventricular arrhythmias, extending its integrated mapping, pulsed-field and radiofrequency ablation workflow into ventricular procedures. Representative image.
Medical Devices & Diagnostics

Why Thermedical’s Durablate catheter could address difficult-to-reach heart arrhythmias

Thermedical names nine experts to oversee pivotal SERF ablation testing after promising early results. Safety and six-month recurrence remain key tests.

Read More
Representative image: Laboratory analysis of T-cell lymphoma samples as Corvus Pharmaceuticals reports durable soquelitinib responses in final Phase 1/1b data, supporting its ongoing pivotal Phase 3 peripheral T-cell lymphoma trial.
Pharma & Biotech

Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma

Final results from Germany's 109-patient MINT study show a 62.4% best overall response rate and median time to next treatment of 14.9 months with Poteligeo. The findings support its established role in cutaneous T-cell lymphoma while highlighting meaningful toxicity, concurrent treatment and observational-study limitations.

Read More
Pharma & Biotech

Artemis Care Compass and AiVA bring AI-powered workflow tools to fertility clinics

IVI RMA launches AiVA on its Artemis fertility platform across North America. See how AI could improve clinic workflows and patient care.

Read More